Attitudes of European psychiatrists on psychedelics: a cross-sectional survey study.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
12 Aug 2024
12 Aug 2024
Historique:
received:
03
10
2023
accepted:
06
08
2024
medline:
13
8
2024
pubmed:
13
8
2024
entrez:
12
8
2024
Statut:
epublish
Résumé
Research and public interest in psychedelic-assisted psychotherapy (PAP) are growing. This study investigated attitudes toward psychedelics among a diverse and multinational sample of psychiatrists currently working in Europe. We conducted an anonymous, web-based survey consisting of demographic information, a test of basic knowledge on psychedelics, and the previously validated 20-item Attitudes on Psychedelics Questionnaire (APQ), which was validated for the first time in English within this sample. We included N = 419 participants from 33 countries in the study. One-third of participants (34%) reported past use of psychedelics. The APQ sub-scale with the highest score was Openness to Psychedelics, while Risk Assessment of Psychedelics was rated lowest. Regression modelling, explaining 31.3% of variance in APQ scores, showed that younger male psychiatrists who identified as spiritual, were better at recognizing and classifying substances as psychedelics and had previously used psychedelics had more positive attitudes on psychedelics. No professional variables besides self-reported previous experience with PAP or psychedelic research predicted APQ scores. European psychiatrists, therefore, show a general openness to psychedelics and PAP, but are concerned by the potential risks associated with them. Our findings overall suggest that psychedelics are a subject where it is difficult to remain impartial. Protocol registration: The study was pre-registered at the Open Science Framework (available online at https://osf.io/upkv3 ).
Identifiants
pubmed: 39134670
doi: 10.1038/s41598-024-69688-7
pii: 10.1038/s41598-024-69688-7
doi:
Substances chimiques
Hallucinogens
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
18716Informations de copyright
© 2024. The Author(s).
Références
Carhart-Harris, R. L. & Goodwin, G. M. The Therapeutic potential of psychedelic drugs: Past, present, and future. Neuropsychopharmacology 42, 2105–2113. https://doi.org/10.1038/npp.2017.84 (2017).
doi: 10.1038/npp.2017.84
pubmed: 28443617
pmcid: 5603818
Sessa, B. Turn on and tune in to evidence-based psychedelic research. Lancet Psychiatry 2, 10–12. https://doi.org/10.1016/S2215-0366(14)00120-5 (2015).
doi: 10.1016/S2215-0366(14)00120-5
pubmed: 26359597
Schlag, A. K., Aday, J., Salam, I., Neill, J. C. & Nutt, D. J. Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. J. Psychopharmacol. 36, 258–272. https://doi.org/10.1177/02698811211069100 (2022).
doi: 10.1177/02698811211069100
pubmed: 35107059
pmcid: 8905125
Pilecki, B., Luoma, J. B., Bathje, G. J., Rhea, J. & Narloch, V. F. Ethical and legal issues in psychedelic harm reduction and integration therapy. Harm Reduct. J. 18, 40. https://doi.org/10.1186/s12954-021-00489-1 (2021).
doi: 10.1186/s12954-021-00489-1
pubmed: 33827588
pmcid: 8028769
Anderson, B. T., Danforth, A. L. & Grob, C. S. Psychedelic medicine: Safety and ethical concerns. Lancet Psychiatry 7, 829–830. https://doi.org/10.1016/s2215-0366(20)30146-2 (2020).
doi: 10.1016/s2215-0366(20)30146-2
pubmed: 32949507
Kisely, S. The down-scheduling of MDMA and psilocybin(e): Too fast and too soon. Aust. N. Z. J. Psychiatry 57, 933–934. https://doi.org/10.1177/00048674231174171 (2023).
doi: 10.1177/00048674231174171
pubmed: 37161273
pmcid: 10291367
European Psychiatric Association. European union funds groundbreaking research into psychedelic therapy. https://www.europsy.net/european-union-funds-groundbreaking-research-into-psychedelic-therapy/ (2024).
Barnett, B. S., Siu, W. O. & Pope, H. G. Jr. A survey of american psychiatrists’ attitudes toward classic hallucinogens. J. Nerv. Ment. Dis. 206, 476–480. https://doi.org/10.1097/NMD.0000000000000828 (2018).
doi: 10.1097/NMD.0000000000000828
pubmed: 29781894
Davis, A. K., Agin-Liebes, G., Espana, M., Pilecki, B. & Luoma, J. Attitudes and beliefs about the therapeutic use of psychedelic drugs among psychologists in the United States. J. Psychoact. Drugs 54, 1–10. https://doi.org/10.1080/02791072.2021.1971343 (2021).
doi: 10.1080/02791072.2021.1971343
Ginati, Y. D. et al. A nationwide study comparing mental health professionals’ willingness to try hallucinogenic drugs in basic research or clinical practice. J. Psychoact. Drugs 54, 177–187. https://doi.org/10.1080/02791072.2021.1941444 (2022).
doi: 10.1080/02791072.2021.1941444
Barnett, B. S., Beaussant, Y., King, F. T. & Doblin, R. Psychedelic knowledge and opinions in psychiatrists at two professional conferences: An exploratory survey. J. Psychoact. Drugs 54, 269–277. https://doi.org/10.1080/02791072.2021.1957183 (2022).
doi: 10.1080/02791072.2021.1957183
Hearn, B. G., Brubaker, M. D. & Richardson, G. Counselors’ attitudes toward psychedelics and their use in therapy. J. Couns. Dev. 100, 364–373. https://doi.org/10.1002/jcad.12429 (2022).
doi: 10.1002/jcad.12429
Schmidt, C., Wolff, M., Grunder, G. & Jungaberle, H. Attitudes of mental health experts towards psilocybin. Fortschr. Neurol. Psychiatr. 91, 80–87. https://doi.org/10.1055/a-1846-1161 (2023).
doi: 10.1055/a-1846-1161
pubmed: 35724682
Page, L. A., Rehman, A., Syed, H., Forcer, K. & Campbell, G. The readiness of psychiatrists to implement psychedelic-assisted psychotherapy. Front. Psychiatry 12, 743599. https://doi.org/10.3389/fpsyt.2021.743599 (2021).
doi: 10.3389/fpsyt.2021.743599
pubmed: 35756728
pmcid: 9231579
Wells, A., Fernandes, M. & Reynolds, L. Perceptions and attitudes towards psychedelic-assisted psychotherapy among health professionals, patients, and the public: A systematic review. J. Psychedelic Stud. 8(1), 43–62. https://doi.org/10.1556/2054.2023.00294 (2024).
doi: 10.1556/2054.2023.00294
Žuljević, M. F. et al. Validation of a new instrument for assessing attitudes on psychedelics in the general population. Sci. Rep. 12, 18225. https://doi.org/10.1038/s41598-022-23056-5 (2022).
doi: 10.1038/s41598-022-23056-5
pubmed: 36309539
pmcid: 9617880
Fazio, R. H. & Zanna, M. P. Direct experience and attitude-behavior consistency. Adv. Exp. Soc. Psychol. 14, 161–202. https://doi.org/10.1016/S0065-2601(08)60372-X (1981).
doi: 10.1016/S0065-2601(08)60372-X
Byrnes, J. P., Miller, D. C. & Schafer, W. D. Gender differences in risk taking: A meta-analysis. Psychol. Bull. 125, 367–383. https://doi.org/10.1037/0033-2909.125.3.367 (1999).
doi: 10.1037/0033-2909.125.3.367
Hartogsohn, I. American Trip: Set, Setting, and the Psychedelic Experience in the Twentieth Century (The MIT Press, Cambridge, 2020).
doi: 10.7551/mitpress/11888.001.0001
Stevens, J. Storming Heaven: LSD and the American Dream (Grove Press, New York, 1998).
Timmermann, C. et al. Psychedelics alter metaphysical beliefs. Sci. Rep. 11, 22166. https://doi.org/10.1038/s41598-021-01209-2 (2021).
doi: 10.1038/s41598-021-01209-2
pubmed: 34815421
pmcid: 8611059
Nayak, S. M., Singh, M., Yaden, D. B. & Griffiths, R. R. Belief changes associated with psychedelic use. J. Psychopharmacol. 37, 80–92. https://doi.org/10.1177/02698811221131989 (2023).
doi: 10.1177/02698811221131989
pubmed: 36317643
Nayak, S. M. & Griffiths, R. R. A single belief-changing psychedelic experience is associated with increased attribution of consciousness to living and non-living entities. Front. Psychol. 13, 852248. https://doi.org/10.3389/fpsyg.2022.852248 (2022).
doi: 10.3389/fpsyg.2022.852248
pubmed: 35418909
pmcid: 8995647
Romeo, B., Hermand, M., Petillion, A., Karila, L. & Benyamina, A. Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review. J. Psychiatr. Res. 137, 273–282. https://doi.org/10.1016/j.jpsychires.2021.03.002 (2021).
doi: 10.1016/j.jpsychires.2021.03.002
pubmed: 33730602
Kopra, E. I. et al. Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the global drug survey 2020. J. Psychopharmacol. 37, 2698811231158245. https://doi.org/10.1177/02698811231158245 (2023).
doi: 10.1177/02698811231158245
Passie, T. & Brandt, S. D. Self-experiments with psychoactive substances: A historical perspective. In New Psychoactive Substances: Pharmacology Clinical, Forensic and Analytical Toxicology (eds Maurer, H. H. & Brandt, S. D.) 69–103 (Springer, Cham, 2018).
doi: 10.1007/164_2018_177
Eurostat. Mental health: How many psychiatrists in the EU? https://ec.europa.eu/eurostat/web/products-eurostat-news/-/edn-20171010-1 (2023).
SurveyMonkey. Sample size calculator. https://www.surveymonkey.com/mp/sample-size-calculator/ (2023).
Hu, L. T. & Bentler, P. M. Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. Struct. Equ. Model. A Multidiscip. J. 6, 1–55. https://doi.org/10.1080/10705519909540118 (1999).
doi: 10.1080/10705519909540118